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Abstract
Background: The effects of pulmonary arterial hypertension on cardiovascular and physical function are
well documented. Limited information exists regarding the effects of pulmonary arterial hypertension on
cognitive function despite patient reports of problems with memory and attention. Our primary purpose
was to determine if a prospectively identified cohort of pulmonary arterial hypertension patients had
cognitive sequelae. Our secondary purpose was to determine the relationships between cognitive
sequelae and neuropsychological test scores with depression, anxiety, and quality of life.
Methods: Forty-six adults with pulmonary arterial hypertension underwent assessment of cognitive
function, depression, anxiety, and quality of life using standardized neuropsychological tests and
questionnaires. The patients' scores were compared to normal population data. Medical, affective,
neuropsychological, and quality of life data for patients with and without cognitive sequelae were
compared using analysis of variance, Chi-square, or Fisher exact tests for categorical data. Correlations
assessed relationships between neuropsychological test scores, depression, anxiety, quality of life, and
medical data.
Results: Cognitive sequelae occurred in 58% (27/46) of the pulmonary arterial hypertension patients.
Patients with cognitive sequelae had worse verbal learning, delayed verbal memory, executive function,
and fine motor scores compared to patients without cognitive sequelae. Twenty-six percent of patients
had moderate to severe depression and 19% had moderate to severe anxiety. Depression, anxiety and
quality of life were not different for patients with or without cognitive sequelae. Our patients had
decreased quality of life, which was associated with worse working memory.
Conclusion: Patients with pulmonary arterial hypertension have cognitive impairments, depression,
anxiety, and decreased quality of life. Depression, anxiety, and quality of life were similar for patients with
cognitive sequelae compared to those without cognitive sequelae. Decreased quality of life was associated
with worse verbal and working memory. Clinicians should be aware of adverse brain related outcomes in
PAH patients. Attention to proximal determinants and possible interventions to prevent or reduce
cognitive and emotional morbidity and decreased quality of life are warranted and should be an emphasis
in outcomes research.
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Pulmonary arterial hypertension (PAH) are a group of dis-
eases where obstructive pathologic changes occur in the
small musculature of the pulmonary arteries [1]. Pulmo-
nary arterial hypertension is characterized by shortness of
breath, chest pain, edema, and syncope and is associated
with life-threatening right heart failure [2]. Diagnostic
classification includes familial PAH and idiopathic PAH
which occurs in association with collagen vascular dis-
ease, congenital systemic to pulmonary shunts, portal
hypertension or exposure to drugs and toxins. Although
the pathogenesis of PAH is not completely understood,
widely accepted mechanisms include vasoconstriction,
endothelial dysfunction and smooth muscle cell prolifer-
ation, and thombosis [3]. Therapies such as calcium chan-
nel antagonists, prostacyclin analogues,
phosphodiesterase-5 inhibitors, and endothelin receptor
antagonists have reduced mortality, improved functional
abilities, and improved quality of life [4].
Studies of the natural history of PAH found the median
length of survival was 2.8 years [5]. While PAH patients
are living longer, decreased exercise tolerance [6], reduced
energy, and limited physical mobility are common [7].
Depression, anxiety, and decreased quality of life are also
reported [7]. While the effects of PAH on cardiovascular
and physical function are well documented, less is known
regarding the effects of PAH on the brain and cognitive
function despite patient reports of problems with mem-
ory and attention [8]. Cognitive function, emotional func-
tion, and quality of life are important as many PAH
patients are living longer and may develop brain related
morbidity.
We previously reported that telephone administered neu-
ropsychological tests to assess cognitive function in PAH
patients were reliable and valid [9]. Cognitive impair-
ments and their associations with depression, anxiety, and
quality of life in patients with PAH have not been
described. We reasoned that PAH patients may have sim-
ilar cognitive impairments to those observed in disorders
characterized hypoxemia [10-12] and right heart failure
[13]. Our primary purpose was to determine if a prospec-
tively identified cohort of patients with PAH have cogni-
tive sequelae. Our secondary purpose was to determine
the relationships between cognitive sequelae and neu-




Consecutive PAH patients were prospectively recruited
from the pulmonary hypertension clinic at LDS Hospital,
in Salt Lake City, Utah. LDS Hospital is a major referral
and tertiary care center with a moderately large PAH pop-
ulation. Eligible PAH patients diagnosed by PAH by a
board certified pulmonologist (CGE) based on clinical
and laboratory data, and the 2003 World Health Organi-
zation classification guidelines were evaluated for this
study. Study exclusion criteria were prior traumatic brain
injury, neurologic disease (i.e., multiple sclerosis, stroke,
dementia, etc.), psychiatric disorders with psychosis, co-
morbid disease with known cognitive impairments (i.e.,
HIV, chronic obstructive pulmonary disease, coronary
artery bypass surgery, cerebral ischemia), non-English
speaking, and pulmonary hypertension not PAH. The LDS
Hospital Institutional Review Board approved this study
and it conformed to institutional and federal guidelines
for the protection of human subjects. All patients signed
statements of informed consent.
Study design and methods
There were 95 patients with pulmonary hypertension of
which 30 were excluded, due to diagnosis not PAH (n =
28) and English not their primary language (n = 2). Of the
65 eligible PAH patients 15 declined the study, 2 had
medical complications, 2 we were not able to contact, and
2 patients died prior to study enrolment resulting in 46
enrolled patients. All patients received normal clinical
care and treatment in the pulmonary hypertension clinic.
Patient medical data were collected prospectively as part
of routine clinical care. The medical data included New
York Heart Association (NYHA) functional classification,
medications, supplemental oxygen use, 6-minute walk
data, Borg dyspnea index, and laboratory data. Demo-
graphic data including age, gender, education level, and
psychiatric history were obtained as part of the neuropsy-
chological assessment. In order to ensure the patient's
oxygen levels were within the normal range during neu-
ropsychological testing, pre- and post-testing oxygen satu-
ration (SpO2) and heart rate were obtained using a Nonin
pulse oximeter [14]. Patients that required oxygen therapy
were tested on supplemental oxygen.
Cognitive outcome
Standardized neuropsychological tests were administered
in a quiet private office at LDS Hospital. The neuropsy-
chological tests assessed general intelligence, attention,
memory, mental processing speed, executive function (i.e.
decision making, organization, problem solving, etc.),
and fine motor abilities. The neuropsychological tests are
sensitive to cognitive impairments, with known reliability
and validity and are widely used in a variety of clinical,
medical, psychiatric, and research populations.
General intellectual functioning was assessed using the
Weschler Abbreviated Scale of Intelligence (WASI; mean =
100, SD = 15) [15]. To determine the possible effects of
PAH on general intellectual functioning, the National
American Adult Reading Test (NAART) was used to assessPage 2 of 10
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Total Group
 (N = 46)
Cognitive Sequelae
 (N = 27)
No Cognitive Sequelae
 (N = 19)
Cognitive Sequelae vs. 
No Cognitive
 Sequelae P value
Gender Female N (%) 38 (82.6%) 23 (60.5%) 14 (39.5%) 0.43
Age in years M ± SD 
(range)
48.2 ± 11.8 (20 to 69) 48.6 ± 11.8 (24 to 69) 47.6 ± 12 (20 to 65) 0.78
Education in years M ± SD 
(range)
13.6 ± 3.0 (4 to 8) 13.3 ± 3.3 (4 to 18) 14.1 ± 2.4 (11 to18) 0.37
Time from PAH Diagnosis 
to testing in years M ± SD 
(range)
2.6 ± 2.6 (0.08 to 11.9) 2.0 ± 1.4 (0.08 to 5.2) 3.4 ± 3.5 (0.08–11.9) 0.07
New York Heart 
Classification: N (%)
Class I 2 (4.3) 2 0 0.17
Class II 9 (19.6) 5 4 0.47
Class III 34 (67.4) 11 23 0.10
Class IV 1 (2.2) 0 1 0.99
Etiology of PAH: N (%)
Drug/Toxin 16 (34.8) 6 10 0.77
Primary Pulmonary 
Hypertension
19 (40) 10 9 0.23
Collagen Vascular 
Disease
8 (17.4) 3 5 0.82
Portal Hypertension 2 (4.3) 0 2 0.50
Congenital systemic-to- 
pulmonary shunt
1 (2.2) 0 1 0.50
Medications: N (%)
Vasodilators 25 (54.3) 9 16 0.32
Calcium Channel 
Blockers
16 (34.8) 9 7 0.13
Endothelial Receptor 
Antagonists
15 (32.6) 6 9 0.59
Anticoagulants 30 (65.2) 13 17 0.48
Prostacyclins
Epoprostenol 12 (25.5) 6 6 0.48
Treprostinil 16 (34.8) 10 6 0.71
Supplemental Oxygen: N 
(%)
30 (65.2) 10 20 0.11
Oxygen Daytime: liters/
minute
2.84 3.0 2.6 0.54
Oxygen Night: liters/
minute
2.90 2.9 2.8 0.84
Medical Variables M ± SD
PaO2
Diagnostic 63.7 ± 12.5 62.2 ± 15 65.6 ± 8.0 0.39
Most Recent (N = 30) 68.0 ± 9.8 66.3 ± 10 70.4 ± 9.3 0.27
Mean Right Atrial Pressure 
(mmHg)
Diagnostic 12.1 ± 6.9 11.4 ± 5.7 13.0 ± 8.5 0.45
Most Recent (N = 34) 11.0 ± 5.4 10.9 ± 5.6 11.1 ± 5.1 0.92
Mean Pulmonary Capillary 
Wedge Pressure (mmHg)
Diagnostic 11.4 ± 4.5 11.6 ± 4.8 11.1 ± 4.1 0.75
Most Recent (N = 33) 11.2 ± 5.3 11.4 ± 5.5 10.9 ± 5 0.79
Mean Pulmonary Artery 
Pressure (mmHg)
Diagnostic 53.6 ± 13.9 52.1 ± 13.1 55.5 ± 15.2 0.42
Most Recent (N = 34) 52.7 ± 13.5 55.6 ± 13.7 48.8 ± 12.5 0.15
Mean Cardiac Output 
(thermo; L/min)
Diagnostic 4.4 ± 1.8 4.2 ± 1.8 4.6 ± 1.8 0.48
Most Recent (N = 31) 4.5 ± 1.6 4.4 ± 1.5 4.5 ± 1.8 0.87Page 3 of 10
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quickly administered index that is widely used to estimate
intellectual ability. The predicted intellectual function
from the NAART can be compared with current perform-
ance to determine the extent of intellectual decline. The
NAART has been shown to be valid in estimating premor-
bid intellectual function in a variety of neurologic popu-
lations [16]. The NAART yields intelligence quotient (IQ)
score (mean = 100, SD = 15) and the estimated premorbid
IQ score was compared to the measured Full Scale Intelli-
gence Quotient (IQ) from the WASI.
Memory was assessed using the Logical Memory I and II
subtests from the Weschler Memory Scale-III (WMS-III)
[17], Rey Complex Figure Test [18], and Rey Auditory Ver-
bal Learning Test [16]. Executive Functioning was assessed
using the Trail Making Test Parts A and B [19], Wisconsin
Card Sorting Test [16], and Hayling Sentence Completion
Test [20]. Attention was assessed using the Stroop Test
[16], Ruff 2&7 Selective Attention Test [21], and Digit
Span from the WMS-III. Mental processing Speed was
assessed using Symbol Digit subtest from the WMS-III.
Motor function was assessed using the Grooved Pegboard
[22], and Finger Tapping tests [22]. Scores were calculated
using published population normative data for each test
and were transformed to age and gender corrected T-
Scores [16,23]. T-scores have a mean of 50 and standard
deviation of 10 and allow for comparison across cognitive
test scores and patients.
Cognitive sequelae (presence or absence) was defined a
priori as 2 or more neuropsychological test scores that
were >1.5 SD or 1 test score that was >2 SD below the nor-
mative population data. Our definition of cognitive
sequelae is similar to those used by others and ourselves
in previous studies [24,25]. We also report the percent of
patients with cognitive impairments for each cognitive
domain (e.g. memory, mental processing speed, atten-
tion, executive function, and motor function).
Depression and anxiety
Depression and anxiety were measured using the Beck
Depression Inventory (BDI) [26] and Beck Anxiety Inven-
tory (BAI) [27]. For the BDI scores of 0 to 9 indicate min-
imal depression, 10 to 16 mild, 17 to 29 moderate, and 30
to 63 severe depression. For the BAI scores of 0 to 7 indi-
cate minimal anxiety, 8 to 15 mild, 16 to 25 moderate,
and 26 to 63 severe anxiety.
Quality of life
The Medical Outcome Study 36-Item Short Form Health
Survey (SF-36) [28] was administered to assess quality of
life. The eight domains of the SF-36 (physical functioning,
role-physical, bodily pain, general health, vitality, social
functioning, role-emotional, and mental health) are clus-
tered to form two higher order domains, the physical and
mental health scores. Each domain is scored from 0 to
100, with higher scores indicating better quality of life.
The SF-36 has been used in a variety of patient popula-
tions and norms for age and gender are available [28,29].
Statistical analyses
Descriptive statistics were carried out for demographic,
medical, neuropsychological, and quality of life scores
and are reported as mean ± standard deviation. Pre- and
post-neuropsychological test oxymetric oxygen saturation
(SpO2) and heart rate were compared using paired t-tests.
The patient's measured Full Scale IQ (WASI) was com-
pared to the estimated premorbid Full Scale IQ (NAART
score) using paired t-tests. Cognitive sequelae are reported
as percentage of patients. Data for depression (BDI) and
anxiety (BAI) are reported as the percentage of patients.
Medical, affective, neuropsychological, and quality of life
data for patients with cognitive sequelae and without cog-
nitive sequelae were compared using analysis of variance
(ANOVA) for continuous data and Chi square or Fisher
exact tests for categorical data.
Pearson's Product Moment correlations were used to
assess the relationships between neuropsychological test
scores, depression, anxiety, and quality of life and medical
data. Correlation coefficients were considered significant
at a 0.01 two-sided significance level in order to reduce
the number of spuriously significant findings resulting
from multiple comparisons.
Mean Cardiac Index 
(thermo; L/min)
Diagnostic 2.4 ± 0.8 2.2 ± 0.7 2.6 ± 0.7 0.27
Most Recent (N = 10) 2.4 ± 0.5 2.7 ± 0.4 2.2 ± 0.3 0.06
Pulmonary Vascular 
Resistance (Woods unit)
Diagnostic 11.4 ± 5.2 11.6 ± 5 11.1 ± 5.4 0.77
Most Recent (N = 30) 11.1 ± 6.1 11.6 ± 6.6 10.4 ± 5.6 0.58
PAH = Pulmonary Arterial Hypertension
Diagnostic = Taken from data obtained at the time of PAH diagnosis
Most Recent = Taken from the patients most recent laboratory and right hearth catheterization data.
Table 1: Demographic and Medical Data (Continued)Page 4 of 10
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Total Group
 M ± SD
Cognitive Sequelae
 M ± SD
No Cognitive
 Sequelae M ± SD
Cog. Sequelae vs. No 
Cog.
 Sequelae P value
WASI
Full Scale IQ 103 ± 12.0 100 ± 13.5 107 ± 7.8 0.06
NAART Estimated 
Premorbid IQ
Full Scale Intelligence 
Quotient
111 ± 9.1 109 ± 9.9 114 ± 6.9 0.13
Memory
Rey Auditory Verbal 
Learning Test (Raw 
Scores)
Trial 1 6.2 ± 1.9 5.7 ± 1.8 6.8 ± 1.7 0.04
Trial 5 12.3 ± 2.3 11.5 ± 2.5 13.3 ± 1.4 0.01
Immediate Recall 10.5 ± 3.2 9.7 ± 3.3 11.5 ± 2.8 0.07
Delayed Recall 10.3 ± 3.3 9.8 ± 3.6 10.8 ± 2.7 0.29
Logical Memory 
(Percentile)
Immediate Recall 41.4 ± 27.8 32.5 ± 26.1 54.0 ± 25.6 0.08
Delayed Recall 41.9 ± 27.4 32.2 ± 24.4 55.8 ± 25.8 0.03
Rey Complex Figure 
Test (T-scores)
Immediate Recall 49.8 ± 14.9 46.8 ± 15.1 54.1 ± 13.8 0.88





9.5 ± 2.8 8.9 ± 2.9 10.2 ± 2.4 0.27
Digit Span (T-score) 59.9 ± 10.4 58.6 ± 10.8 61.7 ± 9.7 0.32
Ruff 2&7 Test (T-
scores)
Total Speed 58.0 ± 10.9 56 ± 11.6 61.0 ± 9.3 0.11
Total Accuracy 44.8 ± 12.5 45 ± 14.7 44.5 ± 8.6 0.89
Stroop Color-Word T-
score
48.2 ± 14.5 47 ± 14.5 49.8 ± 14.7 0.91
Executive Function
Trail Making Test (T-
scores)
Part A 50.3 ± 10.1 49.3 ± 10.3 51.6 ± 9.8 0.45




46.1 ± 9.9 44.8 ± 8.2 48.1 ± 12 0.28
Perseverative Errors 
(T-score)
48.4 ± 7.9 46.4 ± 8.4 51.4 ± 6.0 0.04
Number Categories 
Completed
5.2 ± 1.3 4.9 ± 1.4 5.6 ± 0.8 0.07
Hayling Sentence 
Completion Test
Total Score (Scaled 
Score)
5.6 ± 1.7 5.5 ± 2.0 5.8 ± 0.9 0.55
Mental Processing 
Speed
Symbol Digit (Raw 
Score)
52.6 ± 13.8 51.7 ± 14.8 50.8 ± 17.5 0.86
Motor Function (T-
scores)
Finger Tapping Right 
hand
58.1 ± 12.1 55.4 ± 12.9 62.6 ± 9.4 0.05
Finger Tapping Left hand 61.7 ± 9.3 59.4 ± 8.2 65.9 ± 9.9 0.03
Grooved Peg Board 
Right hand
43.7 ± 11.5 37.8 ± 10.4 53.2 ± 5.0 <0.001Page 5 of 10
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Descriptive statistics
Descriptive statistics and medical data for the PAH
patients are shown in Table 1. There were 46 PAH patients
enrolled, 38 (82.6%) female, mean age of 48.2 ± 11.8
years (range 20 to 69 years) and a mean education level of
13.6 ± 3 years (range 4 to 18 years). The time from PAH
diagnosis to neuropsychological testing was 2.6 ± 2.6
years. There were no significant differences between the
PAH patients' pre-test SpO2 (92.7 ± 3.9%) and post-test
SpO2 (92.5 ± 3.3%; p = 0.43) and pre-test heart rate (84.9
± 13.2) and post-test heart rate (83.5 ± 14.4; p = 0.66).
The PAH patient's estimated mean premorbid IQ (111 ±
9.1) was significantly higher than their measured mean
Full Scale IQ (103 ± 12; t = 6.41, p < 0.0001). Fifty-eight
percent (27/46) of the PAH patients had cognitive seque-
lae 2.6 years (mean) following diagnosis. In individual
cognitive domains, 56.5% (26/46) had impaired motor
function, 41.3% (19/46) had impaired memory, 17.4%
(8/46) had slow mental processing speed, 15.2% (7/46)
had executive dysfunction, and 13.5% (6/46) had
impaired attention. Table 2 outlines neuropsychological
test scores.
The mean BDI scores were 13 ± 8.3 (range 0 to 39) and the
mean BAI scores were 12.4 ± 10.3 (range 0 to 43). Twenty-
six percent of patients had moderate to severe symptoms
of depression and 19.6% had moderate to severe symp-
toms of anxiety. The PAH patients had decreased quality
of life compared to normals as depicted in Table 3.
Comparison of patients with and without cognitive 
sequelae
Patients with cognitive sequelae had significantly lower
scores compared to those with no cognitive sequelae
(Table 2) for: 1) verbal learning [RAVLT trial 1; F(1,44) =
4.45, p = 0.043 and RAVLT trial 5; F(1,44) = 6.98, p =
0.002]; 2) immediate verbal memory [LM I; F(1,44) =
7.68, p < 0.008]; 3) delayed verbal memory [LM II;
F(1,44) = 9.91, p < 0.003]; 4) executive function [WCST
perseverative errors; F(1,42) = 4.48, p = 0.04]; and 5)
motor function [finger tapping right; F(1,41) = 3.78, p <
0.05, finger tapping left; F(1,41) = 5.22, p = 0.03, and
grooved pegboard right, F(1,41) = 30.18, p < 0.001].
There were no significant differences between patients
with and without cognitive sequelae for depression [BDI;
F(1,43) = 0.003, p = 0.95)] or anxiety [BAI; F(1,43) = 1.04,
p = 0.31]. There were no significant differences in SF-36
scores of the PAH patients with and without cognitive
sequelae (p = 0.06 to 0.99; Table 3).
Correlations
There were no significant correlations between any medi-
cal variable and neuropsychological test scores. There
were no significant correlations between depression and
neuropsychological test scores. Anxiety correlated with
worse delayed verbal memory (RAVLT delay recall; r = -
.36, p < 0.002) and working memory (Letter-Number
Sequencing; r = -.35, p ≤ 0.02).
For the quality of life, worse working memory (Letter-
Number Sequencing) correlated with lower Role Physical
Grooved Peg Board Left 
hand
42.8 ± 12.7 41.0 ± 13.8 46.1 ± 9.7 0.21
Neuropsychological scores are presented as Mean ± Standard Deviation (M ± SD). WASI = Wechsler Abbreviated Scale of Intelligence, scores are 
presented as intelligence quotients (M = 100, SD = 15). The T-scores are age, gender and education corrected scores (Mean = 50, SD = 10). 
Abbreviations are as follows: IQ = Intelligence Quotient; NAART = North American Adult Reading Test; and WCST = Wisconsin Card Sorting 
Test.
Table 2: Neuropsychological Test Scores (Continued)
Table 3: Health-related Quality of Life Data
Total PAH group 
(N = 46)
 Mean ± SD
Normals Cognitive Sequelae 
(N = 27)
 M ± SD
No Cognitive 








General Health 37.6 ± 19.2 77 37.7 ± 18.6 37.6 ± 20.7 0.99
Physical Health 36.6 ± 23.5 82 35.7 ± 18.3 37.8 ± 30.3 0.78
Role Physical 37.2 ± 37.9 81 28.6 ± 35.2 50.0 ± 39.3 0.06
Role Emotional 69.6 ± 42.5 83 61.7 ± 46.0 81.5 ± 34.7 0.13
Social Functioning 55.1 ± 29.4 82 52.5 ± 25.6 58.7 ± 34.6 0.52
Bodily Pain 61.2 ± 24.3 79 60.8 ± 26.0 61.8 ± 22.3 0.89
Vitality 36.7 ± 22.1 65 35.7 ± 22.0 38.1 ± 23.0 0.74
Mental Health 52.0 ± 35.5 80 55.0 ± 33.9 47.6 ± 38.5 0.52Page 6 of 10
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Physical (r = -.41, p ≤ 0.001), Role Emotional (r = -.52, p
≤ 0.001), and Social Functioning (r = -.43, p = 0.005).
Depression correlated with lower Vitality (r = -.44, p =
0.005) and Social Functioning (r = -.58, p ≤ 0.001).
Discussion
Our patients' estimated premorbid IQ was in the high
average range and was higher than their measured Full
Scale IQ, suggesting a modest decline in intellectual func-
tion. Over half (58%) of our PAH patients had cognitive
sequelae. The prevalence of cognitive sequelae in our PAH
patients is similar to that observed following carbon mon-
oxide poisoning [25]. obstructive sleep apnea [10], and
following coronary artery bypass graft surgery [24]. The
rate of cognitive sequelae was higher than one (45%) and
two years (47%) after recovery from acute respiratory dis-
tress syndrome [24] but was similar to the rate (58%)
found in patients with congestive heart failure [30,31].
Our PAH patients were assessed approximately 2.6 years
post-PAH diagnosis and 70% had a NYHA functional clas-
sification of III or IV indicating they were in the advanced
stages of PAH. It is possible that earlier in the course of
PAH patients may have a less severe or a lower rate of cog-
nitive sequelae. Possible mechanisms of the cognitive
impairments include hypoxemia [32] and ischemia
[30,31]. For example, patients with pulmonary disorders
with concomitant hypoxemia have cognitive impair-
ments, especially impaired memory and attention
[33,34].
Our PAH patients have impairments in a variety of cogni-
tive domains including 57% with impaired motor abili-
ties, 40% impaired memory, 17% slow mental processing
speed, 15% executive dysfunction, and 13% impaired
attention. The PAH patients with cognitive sequelae neu-
ropsychological test scores fell below the 8th percentile of
the normal distribution of cognitive function. The
patients found activities that require memory, executive
function, attention, and quick mental processing to be
very difficult or impossible. For example, one patient
reported that her memory problems caused her to make
errors mixing her medication (e.g. flolan) as she would
forget what step she had just completed. To prevent using
incorrectly mixed medication, she would discard the med-
ication and start over, resulting in wasted medication and
increased medication costs.
No significant correlations between medical variables and
neuropsychological test scores were found, likely due to a
restricted range of scores as over half of the patients had
cognitive impairments. One study found that quality of
life was associated with etiology, NYHA class, chest pain,
pre-syncope, abdominal discomfort, and distance walked
in six minutes [35] however cognitive function was not
assessed. It is unclear what role, if any, medical treatment
may play regarding cognitive sequelae in PAH patients, as
we did not assess cognitive function pre- and post-treat-
ment. In addition we did not compare cognitive sequelae
in patients on different medications, as our study was not
designed to compare cognitive outcome by medication
and we did not standardized treatment across patients.
While PAH medications are associated with improvement
in physical function and quality of life [36-38] the effects
of treatment on cognitive function has not been studied.
Of our PAH patients 26% had moderate to severe symp-
toms of depression and 20% had moderate to severe
symptoms of anxiety. Our findings of depression and anx-
iety are similar to previous reports in other pulmonary
hypertension patients [36]. Depression secondary to med-
ical illnesses is common and occurs in 10% of patients in
primary care settings [39]. Depression has been reported
in 25% of patients with chronic cardiac and pulmonary
disorders [40] and anxiety in 10% to 40% of patients with
pulmonary disorders [41]. Only a few studies have
assessed the effects of treatment on depression or anxiety
in patients with pulmonary hypertension. For example,
patients treated with epoprostenol had a lower rate of
depression and anxiety compared to patients who did not
receive it [7].
Anxiety, but not depression correlated with worse verbal
and working memory. There were no other significant cor-
relations with any neuropsychological score. These find-
ings suggest that anxiety, but not depression has a modest
effect on cognitive performance, with verbal memory the
most affected.
The quality of life in this cohort of PAH patients was lower
than that observed in normal individuals [42]. The find-
ing of decreased quality of life in our PAH patients is sim-
ilar to that reported in other PAH patients [7]. Decreased
quality of life has been associated with side effects of med-
ications [43], diuretics [35], and higher NYHA functional
classification [44]. Conversely improved quality of life has
been reported following treatment with epoprostenol [7],
sildenafil [45], inhaled iloprost [46], nifedipine [47], and
lower NYHA class (classes I and II) [45].
Not surprisingly, patients with cognitive sequelae had
lower neuropsychological test scores compared to
patients without cognitive sequelae. There were no differ-
ences for depression or anxiety when comparing PAH
patients with and without cognitive sequelae. Similarly
there were no differences in quality of life in PAH patients
with cognitive sequelae compared to patients without
cognitive sequelae. Cognitive impairments are not associ-
ated with decreased quality of life in ARDS survivors [48]
or medical ICU survivors [49]. In contrast, cognitivePage 7 of 10
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in ICU survivors with multiple trauma [50], in acute res-
piratory distress syndrome [51], following carbon monox-
ide poisoning [52], and in patients with chronic
obstructive pulmonary disease [11]. Cognitive impair-
ments are a major determinant in the ability to return to
work, work productivity, and life satisfaction following
acute respiratory distress syndrome [51]. Even mild cogni-
tive impairments may result in problems in daily func-
tioning such as driving, money management, and
performing activities of daily living [53].
It is unclear why we found no relationship between cogni-
tive sequelae and decreased quality of life in our PAH
patients. One possible reason is that both the PAH
patients with and without cognitive sequelae report very
low quality of life resulting in a restricted range. Thus the
low SF-36 scores occurred in all PAH patients regardless of
presence or absence of cognitive sequelae resulting in
non-significant differences. Another reason for the lack of
relationship between cognitive sequelae and quality of life
is that we did not use a quality of life instrument specific
to PAH. A quality of life instrument specific to PAH might
better assess and detect relationships between quality of
life and cognitive sequelae.
The strengths of this study include a prospective cohort
study design; assessment of oxymetric oxygen saturation
and heart rate pre-and post-neuropsychological testing,
comprehensive neuropsychological measures adminis-
tered in person, and a well defined PAH population.
Limitations of this study include the lack of an appropri-
ate control group from which to make comparisons. How-
ever, we used demographically corrected normal
population data for (i.e. age, gender, and education) to
control for factors known to affect cognitive performance
resulting in improved neurodiagnostic accuracy. A second
limitation is the inability to measure premorbid cognitive
and emotional function, and quality of life similar to
other studies in acute and critically ill patients. A third
limitation is that the observed cognitive sequelae may
have been due to factors other than PAH including age,
premorbid cognitive impairments or comorbid medical
disorders. Evidence suggesting that the cognitive sequelae
are not due to the above factors include 1) It is unlikely
that the observed cognitive sequelae in our PAH patients
were due to pre-existing cognitive impairments because
we screened for patients with prior cognitive impair-
ments. 2) Our patients are younger (mean age 48 ± 12
years) than typically associated with age-related cognitive
impairment or dementia (age ≥ 65 years) and there was
no difference in age of patients with and without cognitive
sequelae. While it is possible to use surrogate screening
tools to detect premorbid cognitive impairments, these
instruments are designed for use in older patients (age ≥
65 years) which is significantly older than most of our
patients. 3) Our patients' education level was high (13.6
years) and there was no difference in education level in
patients with or without cognitive sequelae, thus low edu-
cation level cannot account for the observed cognitive
impairments. 4) Few patients had comorbid disorders
associated with cognitive impairments. Nine patients had
obstructive sleep apnea identified at PAH diagnosis, all of
whom were undergoing treatment at the time of neuro-
cognitive testing, making it difficult if not impossible to
separate the cognitive effects of PAH and from those of
obstructive sleep apnea. Two patients had diabetes and
two had systemic hypertension, all which were treated.
Even if all four of the patients with diabetes and systemic
hypertension had cognitive sequelae, it would not
account for the high rate of cognitive sequelae in our PAH
patients. Therefore it is unlikely pre-existing cognitive
impairments account for the observed cognitive sequelae
in our PAH patients.
Conclusion
Pulmonary arterial hypertension patients have cognitive
impairments, depression, anxiety, and decreased quality
of life. We found no differences for depression, anxiety, or
decreased quality of life for patients with cognitive seque-
lae compared to those without cognitive sequelae.
Decreased quality of life was associated with worse verbal
and working memory. Clinicians should be aware of
adverse brain related outcomes in PAH patients. Attention
to proximal determinants and possible interventions to
prevent or reduce cognitive and emotional morbidity and
decreased quality of life are warranted and should be an
emphasis in outcomes research.
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